Xuan Jing1, Xiangrong Cui2, Hongping Liang1, Chonghua Hao1, Zhining Yang1, Xiaogai Li3, Xiaojuan Yang4, Chongyang Han5. 1. Department of Clinical laboratory, Shanxi Provincial People's Hospital, Affiliate of Shanxi Medical University, Taiyuan, China. 2. Reproductive Medicine Center, Children's Hospital of Shanxi and Women Health Center of Shanxi, Affiliate of Shanxi Medical University, Taiyuan, China. 3. Department of Clinical Laboratory, The First Affiliated Hospital of Zhengzhou University, Key Laboratory of Laboratory Medicine of Henan, Zhengzhou, China. 4. Department of Respiration, Shanxi Provincial People's Hospital, Affiliate of Shanxi Medical University, Taiyuan, China. 5. Department of Nephrology, Shanxi Provincial People's Hospital, Affiliate of Shanxi Medical University, Taiyuan, China.
Abstract
BACKGROUND/AIMS: CD24 is a highly glycosylated mucin-like antigen on the cell surface, which has recently emerged as a novel oncogene and metastasis promoter. We performed bioinformatics analysis to investigate whether CD24 can serve as a prognostic indicator in breast cancer. METHODS: CD24 expression was assessed using SAGE Genie tools and Oncomine analysis. The PrognoScan database, Kaplan-Meier Plotter, and bc-GenExMiner were used to identify the prognostic roles of CD24 in breast cancer. RESULTS: We found that CD24 was more frequently overexpressed in breast cancer than in normal breast tissue and correlated with worse prognosis. Meanwhile, high CD24 expression was associated with increased risk of HER2, basal-like, triple-negative breast cancer, and higher Scarff-Bloom-Richardson grade. Data mining in multiple big databases confirmed a positive correlation between CD24 mRNA expression and SDC1 mRNA expression in breast cancer tissue. CONCLUSIONS: Our findings suggest that CD24 overexpression is more common in breast cancer than in corresponding normal tissue. In addition, CD24 and SDC1 can serve as prognostic indicators for breast cancer. However, large-scale and comprehensive research is needed to further confirm these results.
BACKGROUND/AIMS: CD24 is a highly glycosylated mucin-like antigen on the cell surface, which has recently emerged as a novel oncogene and metastasis promoter. We performed bioinformatics analysis to investigate whether CD24 can serve as a prognostic indicator in breast cancer. METHODS:CD24 expression was assessed using SAGE Genie tools and Oncomine analysis. The PrognoScan database, Kaplan-Meier Plotter, and bc-GenExMiner were used to identify the prognostic roles of CD24 in breast cancer. RESULTS: We found that CD24 was more frequently overexpressed in breast cancer than in normal breast tissue and correlated with worse prognosis. Meanwhile, high CD24 expression was associated with increased risk of HER2, basal-like, triple-negative breast cancer, and higher Scarff-Bloom-Richardson grade. Data mining in multiple big databases confirmed a positive correlation between CD24 mRNA expression and SDC1 mRNA expression in breast cancer tissue. CONCLUSIONS: Our findings suggest that CD24 overexpression is more common in breast cancer than in corresponding normal tissue. In addition, CD24 and SDC1 can serve as prognostic indicators for breast cancer. However, large-scale and comprehensive research is needed to further confirm these results.
Authors: N N Ermakova; O V Pershina; M A Zhukova; A V Pakhomova; E S Pan; L A Sandrikina; V A Krupin; O Yu Rybalkina; A M Dygai; E G Skurikhin Journal: Bull Exp Biol Med Date: 2022-05-02 Impact factor: 0.804
Authors: Ning Xu; Benjamin Tse; Lu Yang; Tiffany C Y Tang; Michelle Haber; Kenneth Micklethwaite; Alla Dolnikov Journal: Immunotargets Ther Date: 2021-04-28
Authors: Birthe Dorgau; Maria Georgiou; Alexander Chaudhary; Marina Moya-Molina; Joseph Collin; Rachel Queen; Gerrit Hilgen; Tracey Davey; Philip Hewitt; Michael Schmitt; Stefan Kustermann; Francois Pognan; David H Steel; Evelyne Sernagor; Lyle Armstrong; Majlinda Lako Journal: Stem Cells Transl Med Date: 2022-03-17 Impact factor: 7.655